WO2010040083A3 - Prédicteurs de chimiorésistance par expression génique - Google Patents
Prédicteurs de chimiorésistance par expression génique Download PDFInfo
- Publication number
- WO2010040083A3 WO2010040083A3 PCT/US2009/059423 US2009059423W WO2010040083A3 WO 2010040083 A3 WO2010040083 A3 WO 2010040083A3 US 2009059423 W US2009059423 W US 2009059423W WO 2010040083 A3 WO2010040083 A3 WO 2010040083A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- chemotherapeutic agent
- methods
- chemoresistance
- gene expression
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des signatures génétiques décrivant des profils génétiques. Les signatures génétiques peuvent prédire si un sujet atteint d'un cancer, tel qu'un cancer de l'estomac, sera chimiorésistant ou chimiosensible à une chimiothérapie à base de cisplatine et de fluorouracile. L'invention décrit ainsi des méthodes permettant de déterminer si un sujet atteint d'un cancer sera sensible à un traitement avec un agent chimiothérapeutique. L'invention décrit des méthodes permettant d'augmenter la sensibilité à l'agent chimiothérapeutique si EGFR, FGFR-2 et MYC sont augmentés, cette augmentation indiquant que le cancer présente une sensibilité diminuée à un agent chimiothérapeutique. L'invention décrit également des méthodes permettant d'augmenter la sensibilité à l'agent chimiothérapeutique si un ou plusieurs marqueurs de cellules souches embryonnaires ou une ou plusieurs cibles MYC sont augmentés, cette augmentation indiquant que le cancer présente une sensibilité diminuée à un agent chimiothérapeutique.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19512308P | 2008-10-03 | 2008-10-03 | |
US61/195,123 | 2008-10-03 | ||
US17839209P | 2009-05-14 | 2009-05-14 | |
US61/178,392 | 2009-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010040083A2 WO2010040083A2 (fr) | 2010-04-08 |
WO2010040083A3 true WO2010040083A3 (fr) | 2010-06-24 |
Family
ID=41506489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/059423 WO2010040083A2 (fr) | 2008-10-03 | 2009-10-02 | Prédicteurs de chimiorésistance par expression génique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010040083A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107254546B (zh) * | 2017-08-16 | 2020-11-03 | 复旦大学附属华山医院 | 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2800311A1 (fr) | 2010-05-11 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Anticorps anti-fgfr2 |
CN106978480A (zh) | 2010-09-15 | 2017-07-25 | 阿尔玛克诊断有限公司 | 用于癌症的分子诊断试验 |
WO2013071502A1 (fr) | 2011-11-17 | 2013-05-23 | Genedia Biotech Co Ltd | Gène mir-193a-3p et gènes associés prédisant la tumorigenèse et les résultats d'une chimiothérapie |
US20150241432A1 (en) * | 2012-07-24 | 2015-08-27 | Cedar-Sinai Medical Center | Novel method to detect resistance to chemotherapy in patients with lung cancer |
EP2695950A1 (fr) * | 2012-08-10 | 2014-02-12 | Blackfield AG | Marqueurs pour la réactivité à un inhibiteur du récepteur du facteur de croissance des fibroblastes |
GB201316027D0 (en) * | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
CN110520543A (zh) * | 2017-03-29 | 2019-11-29 | 中美冠科生物技术(太仓)有限公司 | 确定胃癌对西妥昔单抗敏感性的系统和方法 |
CN111057762B (zh) * | 2019-11-28 | 2022-11-08 | 中国人民解放军陆军军医大学第一附属医院 | 检测基因在制备检测食管鳞癌对顺铂敏感性的制剂中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060037088A1 (en) * | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
-
2009
- 2009-10-02 WO PCT/US2009/059423 patent/WO2010040083A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060037088A1 (en) * | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
Non-Patent Citations (12)
Title |
---|
"[HG-U133A] Affymetrix Human Genome U133A Array", GEO,, 11 March 2002 (2002-03-11), XP002527544 * |
H. K. KIM, I. J. CHOI, C. G. KIM, A. OSHIMA AND J. E. GREEN: "Gene expression signatures to predict the response of gastric cancer to cisplatin and fluorouracil", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15s, 20 May 2009 (2009-05-20), pages 4628, XP002565666, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4628> [retrieved on 20100127] * |
HAMILTON ET AL: "A Review of the Genomics of Gastric Cancer", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 4, no. 4, 1 April 2006 (2006-04-01), pages 416 - 425, XP005367985, ISSN: 1542-3565 * |
HSU DAVID S ET AL: "Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 25, no. 28, 1 October 2007 (2007-10-01), pages 4350 - 4357, XP002513951, ISSN: 0732-183X * |
KIHARA C ET AL: "Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 61, no. 17, 1 September 2001 (2001-09-01), pages 6474 - 6479, XP002960719, ISSN: 0008-5472 * |
KNECHT RAINALD ET AL: "EGFR antibody-supplemented TPF-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 6C, 1 November 2003 (2003-11-01), pages 4789 - 4795, XP009128280, ISSN: 0250-7005 * |
METZGER R ET AL: "ERCC1 MRNA LEVELS COMPLEMENT THYMIDYLATE SYNTHASE MRNA LEVELS IN PREDICTING RESPONSE AND SURVIVAL FOR GASTRIC CANCER PATIENTS RECEIVING COMBINATION CISPLATIN AND FLUOROURACIL CHEMOTHERAPY", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 16, no. 1, 1 January 1998 (1998-01-01), pages 309 - 316, XP001118953, ISSN: 0732-183X * |
NAPIERALSKI RUDOLF ET AL: "Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 8, 15 April 2005 (2005-04-15), pages 3025 - 3031, XP002551877, ISSN: 1078-0432 * |
NISHIMURA T ET AL: "Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.", CLINICAL CANCAR RESEARCH, vol. 2, 1 November 1996 (1996-11-01), pages 1859 - 1865, XP002565665 * |
ROTOLO SABRINA ET AL: "Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells", PLOS ONE, vol. 3, no. 6, June 2008 (2008-06-01), XP002565668, ISSN: 1932-6203 * |
STEWART ET AL: "Mechanisms of resistance to cisplatin and carboplatin", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 63, no. 1, 1 July 2007 (2007-07-01), pages 12 - 31, XP025320373, ISSN: 1040-8428, [retrieved on 20070528] * |
WANG W., ET AL: "Establishment and biological characteristics of a multi-drug resistant cell line A549/Gem", CHIN J LUNG CANCER, vol. 11, no. 1, February 2008 (2008-02-01), pages 55 - 61, XP002565667, Retrieved from the Internet <URL:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path%5B%5D=16&path%5B%5D=20> [retrieved on 20100128], DOI: 10.3779/j.issn.1009-3419.2008.01.014 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107254546B (zh) * | 2017-08-16 | 2020-11-03 | 复旦大学附属华山医院 | 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2010040083A2 (fr) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010040083A3 (fr) | Prédicteurs de chimiorésistance par expression génique | |
WO2010030365A3 (fr) | Identification de tumeurs de la tyroïde | |
WO2008094678A3 (fr) | Signature pronostique moléculaire pour prédire des métastases distantes chez les femmes atteintes d'un cancer du sein, et ses utilisations | |
WO2007082144A3 (fr) | Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine | |
WO2011153254A3 (fr) | Biomarqueurs d'acides nucléiques circulants associés au cancer de la prostate | |
WO2013106844A3 (fr) | Procédés et compositions pour le traitement et le diagnostic du cancer du pancréas | |
WO2012021887A3 (fr) | Biomarqueurs pour la détection précoce du cancer du sein | |
MX340453B (es) | Biomarcadores para cancer de pulmon. | |
EP3543360A3 (fr) | Détection de néoplasme | |
WO2012068400A3 (fr) | Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins | |
EP2276509A4 (fr) | Détection et traitement du cancer du pancréas, des ovaires et d'autres cancers | |
WO2008153987A3 (fr) | Procédés pour la détermination d'un sous-type de carcinome hépatocellulaire et la détection de cellules souches du cancer du foie | |
IN2013CN01129A (fr) | ||
WO2009038754A3 (fr) | Signatures de l'expression génique dans des échantillons de cellules tumorales enrichis | |
WO2010099342A3 (fr) | Procédés de détection du cancer du poumon | |
WO2012074904A3 (fr) | Procédés et systèmes pour l'évaluation de la sensibilité ou de la résistance des échantillons tumoraux vis-à-vis d'agents chimio-thérapeutiques | |
MY170983A (en) | Biomarker assays for detecting or measuring inhibition of tor kinase activity | |
WO2013057581A3 (fr) | Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal | |
EP2611941A4 (fr) | Signatures génétiques pour le diagnostic et le pronostic du cancer | |
WO2010120942A3 (fr) | Modèles de modification des histones utilisables à des fins de diagnostic clinique et de pronostic en matière de cancer | |
WO2009094647A3 (fr) | Biomarqueurs p53 | |
EP2518158A4 (fr) | Marqueurs du cancer du pancréas, méthodes, kits et biopuces de détection associés | |
NZ629555A (en) | Monocyte biomarkers for cancer detection | |
WO2009034481A3 (fr) | Biomarqueur de méthylation pour une détection précoce du cancer gastrique | |
WO2008023840A3 (fr) | Marqueurs pronostiques et cibles thérapeutiques s'appliquant au cancer du poumon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09793289 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09793289 Country of ref document: EP Kind code of ref document: A2 |